Regal Assets Analytics

SanaCurrents on Scholar Rock’s (SRRK) improving treatment for spinal muscular atrophy (SMA)

By |2023-03-20T08:21:36-04:00March 18th, 2023|Tags: |

Scholar Rock Holding Corporatio (NASDAQ:SRRK) Probability Sentiment SUMMARY Spinal muscular atrophy (SMA) is a genetic [...]

SanaCurrents on Wave Life Sciences’ (WVE) precision approach to treating Amyotrophic lateral sclerosis (ALS)

By |2023-03-13T08:46:30-04:00March 11th, 2023|Tags: |

Wave Life Sciences Ltd. (NASDAQ:WVE) Probability Sentiment SUMMARY Approval of Amylyx Pharmaceuticals, Inc.’s (NASDAQ:AMLX) Relyvrio [...]

SanaCurrents on PDUFA decision for SpringWorks (SWTX) first drug to treat desmoid tumors

By |2023-03-06T08:39:47-05:00March 4th, 2023|Tags: |

Springworks Therapeutics, Inc. (NASDAQ:SWTX) Probability Sentiment SUMMARY Desmoid tumors attack the body’s soft tissues, usually [...]

SanaCurrents on the FDA’s lifejacket to Akebia’s (AKBA) anemia drug for dialysis patients

By |2023-02-27T08:32:16-05:00February 25th, 2023|Tags: |

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Probability Sentiment SUMMARY The FDA informed Akebia Therapeutics, Inc. (NASDAQ:AKBA) on [...]

SanaCurrents on Equillium’s (EQ) potential entrant to treat Lupus nephritis (LN)

By |2023-02-21T08:41:03-05:00February 19th, 2023|Tags: |

Equillium, Inc. (NASDAQ:EQ) Probability Sentiment SUMMARY Six-year-old Equillium, Inc.’s (NASDAQ:EQ) lead drug, itolizumab, is in [...]

1 of many SanaCurrents on PDUFA decision for Aldeyra’s (ALDX) new drug to treat dry eye disease

By |2023-02-13T08:34:54-05:00February 12th, 2023|Tags: |

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Probability Sentiment SUMMARY The pipeline at Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) targets [...]

SanaCurrents on Syndax’s (SNDX) rising drug to treat rare, acute leukemias

By |2023-01-17T08:26:57-05:00January 15th, 2023|Tags: |

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Probability Sentiment SUMMARY Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is advancing the small [...]

SanaCurrents on X4 Pharma’s (XFOR) small molecule to treat chronic neutropenia

By |2023-01-09T08:31:40-05:00January 7th, 2023|Tags: |

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Probability Sentiment SUMMARY X4 Pharmaceuticals, Inc.’s (NASDAQ:XFOR) mavorixafor posted impressive clinical [...]

Go to Top